GLAXOSMITHKLINE has a total of 29 patent applications. It increased the IP activity by 0.0%. Its first patent ever was published in 1998. It filed its patents most often in United States, United Kingdom and Australia. Its main competitors in its focus markets pharmaceuticals, organic fine chemistry and biotechnology are AMGEN INC THOUSAND OAKS, IMAGO PHARMACEUTICALS INC and TSENTARIS GMBKH.
# | Country | Total Patents | |
---|---|---|---|
#1 | United States | 13 | |
#2 | United Kingdom | 7 | |
#3 | Australia | 3 | |
#4 | Norway | 3 | |
#5 | Canada | 1 | |
#6 | EPO (European Patent Office) | 1 | |
#7 | WIPO (World Intellectual Property Organization) | 1 |
# | Industry | |
---|---|---|
#1 | Pharmaceuticals | |
#2 | Organic fine chemistry | |
#3 | Biotechnology | |
#4 | Environmental technology | |
#5 | Chemical engineering | |
#6 | Consumer goods |
# | Name | Total Patents |
---|---|---|
#1 | Lewis Alan Peter | 3 |
#2 | Ray Keith Paul | 3 |
#3 | Du Kien S | 2 |
#4 | Boyce Rustum S | 2 |
#5 | Chu Daniel | 2 |
#6 | Speake Jason D | 2 |
#7 | Swain William R | 2 |
#8 | Thomson Stephen A | 2 |
#9 | Naylor Alan | 2 |
#10 | Aurrecoechea Natalia | 2 |
Publication | Filing date | Title |
---|---|---|
GB202005096D0 | Modified vectors for production of retrovirus | |
GB201910020D0 | Novel composition | |
GB201808568D0 | Compounds | |
GB201705853D0 | Novel compounds | |
GB201614942D0 | Novel compounds | |
GB201614945D0 | Novel Compounds | |
GB201416617D0 | Codon optimised lentiviral proteins | |
US6297276B1 | Substituted urea and isothiourea derivatives as no synthase inhibitors | |
US6369272B1 | Nitric oxide synthase inhibitors |